Precision Platform Leverage Closed Loop Medicine's personalized dosing platform as a joint pharmacology and software solution for pharma and health systems seeking precision dosing capabilities. Explore co development licensing and white label integrations with current care pathways.

US Expansion GLP-1 dosing platform launch in the United States signals commercial readiness and a path to payer and provider networks. Target chronic disease clinics, endocrinology practices, and integrated care platforms needing dose optimization for GLP-1 therapies.

Data Ecosystem Proprietary platform integrates medicines with software and patient experiences enabling data rich dosing optimization. Opportunities exist for real world evidence generation, data analytics services, and interoperability with EHRs and digital health tools. Approach health systems, payers, and biopharma with data collaboration proposals.

Leadership Signals Recent leadership changes including a new CEO and board chair indicate strengthened commercialization and governance. This can lower perceived risk for enterprise customers and encourage multi year deals, channel partnerships, and larger procurement engagements.

DTC Momentum Board expansion with direct to consumer medical services and commercialization focus suggests partnerships with consumer health platforms, telemedicine providers, and digital health distributors. Identify opportunities to reach patients with chronic diseases outside traditional care settings through integrated precision care solutions.